Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Pipeline Review, H2 2016’, provides in depth analysis on Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted pipeline therapeutics.

The report provides comprehensive information on the Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B)

The report reviews Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted therapeutics and enlists all their major and minor projects

The report assesses Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Anthera Pharmaceuticals‚ Inc.

Eli Lilly and Company

GlaxoSmithKline Plc

Merck KGaA

Anthera Pharmaceuticals‚ Inc.

Eli Lilly and Company

GlaxoSmithKline Plc

Merck KGaA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Tumor Necrosis ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) Overview 7

Therapeutics Development 8

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Products under Development by Stage of Development 8

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Products under Development by Therapy Area 9

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Products under Development by Indication 10

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Products under Development by Companies 14

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Companies Involved in Therapeutics Development 23

Anthera Pharmaceuticals‚ Inc. 23

Eli Lilly and Company 24

GlaxoSmithKline Plc 25

Merck KGaA 26

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Drug Profiles 27

atacicept - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

belimumab - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

blisibimod - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

BLyS-gel - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Monoclonal Antibodies to Inhibit BAFF for B-Cell Lymphoma - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Monoclonal Antibody to Inhibit BAFF and IL-17 for Immunology - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

OSX-100 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

OSX-110 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

RCT-18 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Dormant Projects 48

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Discontinued Products 49

Tumor Necrosis Factor Ligand Superfamily Member 13B (B Lymphocyte Stimulator or Dendritic Cell Derived TNF Like Molecule or TNF And APOL Related Leukocyte Expressed Ligand 1 or CD257 or TNFSF13B) - Featured News & Press Releases 50

Jun 28, 2016: Anthera Provides Clinical Program Update for Blisibimod 50

Jun 08, 2016: New Phase III data shows greater treatment response with GSK’s Benlysta (belimumab) vs placebo in patients with highly active SLE 51

Mar 03, 2016: New long-term organ damage analysis published for GSK’s Benlysta (belimumab) 53

Nov 07, 2015: GSK announces positive results from phase III BLISS-SC study of Benlysta (belimumab) administered subcutaneously in patients with systemic lupus erythematosus 54

Jun 16, 2015: Anthera Pharmaceuticals Has Reached Enrollment Target in CHABLIS-SC1 Phase 3 Clinical Trial With Blisibimod 55

Jun 04, 2015: Anthera Pharmaceuticals Announces Additional Data on Patient-Reported Outcomes From Phase 2b PEARL-SC Blisibimod Study 56

Mar 16, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for IgA Nephropathy 56

Feb 10, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus 56

Dec 30, 2014: Anthera Pharmaceuticals Announces Lupus Symposium During 2015 JP Morgan Healthcare Conference 57

Oct 01, 2014: Anthera Pharmaceuticals Announces Update On Strategic Partnership Discussions For Blisibimod 58

Sep 25, 2013: Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting 58

Jul 23, 2013: NICE consults on belimumab for systemic lupus erythematosus 59

Jun 24, 2013: Anthera Pharma Initiates BRIGHT-SC Phase II Clinical Study In IgA Nephropathy With Blisibimod 60

May 07, 2013: Anthera Pharma Announces Additional Data From Phase IIb PEARL-SC Blisibimod Study 60

Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis 61

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of ...

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Anthera Pharmaceuticals‚ Inc., H2 2016 23

Pipeline by Eli Lilly and Company, H2 2016 24

Pipeline by GlaxoSmithKline Plc, H2 2016 25

Pipeline by Merck KGaA, H2 2016 26

Dormant Projects, H2 2016 48

Discontinued Products, H2 2016 49

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of ...

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports